Jazz Pharmaceuticals Secures Priority FDA Review for Ziihera GEA Combination
Event summary
- Jazz Pharmaceuticals received FDA acceptance for a supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) in combination therapies for first-line treatment of HER2+ GEA.
- The FDA has assigned a Priority Review designation and a PDUFA target action date of August 25, 2026.
- The submission is based on data from the Phase 3 HERIZON-GEA-01 trial, which demonstrated efficacy with or without Tevimbra® (tislelizumab).
- The FDA granted Breakthrough Therapy Designation for the zanidatamab combination therapy.
The big picture
The approval of Ziihera in this indication represents a significant advancement in the treatment of HER2+ GEA, a cancer with a historically poor prognosis and limited therapeutic options. The combination with tislelizumab, demonstrating efficacy across both PD-L1 positive and negative tumors, addresses a key unmet need. Jazz's partnership with BeOne Medicines and licensing from Zymeworks highlights the increasing complexity of oncology drug development and the reliance on external innovation.
What we're watching
- Clinical Data
- The full HERIZON-GEA-01 trial data, beyond the topline results, will be crucial in understanding the magnitude of benefit and identifying patient populations most likely to respond to the combination therapy.
- Regulatory Risk
- While the Priority Review and Breakthrough Therapy designation expedite the process, the FDA’s Real-Time Oncology Review program doesn’t guarantee approval, and potential safety concerns could still lead to rejection or restrictions.
- Market Adoption
- The success of Ziihera will depend on physician adoption and patient access, which will be influenced by pricing, reimbursement, and competition from existing and emerging HER2-targeted therapies.
Related topics